Efficacy of ciprofloxacin for treatment of cholera associated with diminished susceptibility to ciprofloxacin to vibrio cholerae O1

PLoS ONE

Volumn 10, Issue 8, 2015, Pages

  Khan, Wasif Ali ^a   Saha, Debasish ^a,b   Ahmed, Sabeena ^a   Salam, Mohammed Abdus ^a   Bennish, Michael Louis ^c   Zhou, Dongsheng ^d  

^a INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH   (Bangladesh)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c Mpilonhle ^*  (South Africa)

^d BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CIPROFLOXACIN; NALIDIXIC ACID;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATION; BANGLADESH; CHOLERA; CONTROLLED STUDY; DISK DIFFUSION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SCREENING; HUMAN; INHIBITION ZONE; MAJOR CLINICAL STUDY; MIC50; MIC90; MULTIPLE CYCLE TREATMENT; NONHUMAN; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TREATMENT RESPONSE; VIBRIO CHOLERAE; DOSE RESPONSE; DRUG EFFECTS; FEMALE; GROWTH, DEVELOPMENT AND AGING; ISOLATION AND PURIFICATION; MALE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY;

BANGLADESH; CHOLERA; CIPROFLOXACIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; MALE; NALIDIXIC ACID; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; VIBRIO CHOLERAE;

EID: 84943184130     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0134921     Document Type: Article

References (38)

1. Bennish M.L., Cholera, In Oxford Textbook of Medicine, Warrell D.A., et al., editors. 2003, Oxford University Press: Oxford, United Kingdom. p. 515-521.
2. Nelson E.J., et al, Antibiotics for both moderate and severe cholera. N Engl J Med, 2010. 364(1): p. 5-7. doi: 10.1056/NEJMp1013771 PMID: 21142691
3. Bennish M.L., Cholera: pathophysiology, clinical features, and treatment, In Vibrio cholerae and cholera: molecularto global perspectives, Wachsmuth I.K., Blake P.A., and Olsvik O., editors. 1994, American Society for Microbiology: Washington, D.C. p. 229-55.
4. Bennish M.L., Khan W.A., and Saha D., Vibrio species, In Antimicrobial drug resistance handbook, Mayers D.L., et al., editors. 2008, Wiley: Hoboken, New Jersey, United States of America.
5. Bennish M.L., Treatment and prophylaxis of gastroenteritis, In Quinolone antimicrobial agents, Hooper D.C. and Rubinstein E., editors. 2003, American Society for Microbiology: Washington, D.C. p. 193-216.
6. Saha D., et al., Single-dose ciprofloxacin versus 12-dose erythromycin for childhood cholera: a randomised controlled trial. Lancet, 2005. 366(9491): p. 1085-93. PMID: 16182896
7. Khan W.A., et al, Randomised controlled comparison of single-dose ciprofloxacin and doxycycline for cholera caused by Vibrio cholerae 01 or 0139.: Lancet, 1996. 348(9023): p. 296-300. PMID: 8709688
8. Gotuzzo E., et al, Ciprofloxacin for the treatment of cholera: a randomized, double-blind, controlled clinical trial of a single daily dose in Peruvian adults. Clin Infect Dis, 1995. 20(6): p. 1485-90. PMID: 7548496
9. Saha D., et al., Single-dose azithromycin for the treatment of cholera in adults. N Engl J Med, 2006. 354(23): p. 2452-62. PMID: 16760445
10. Baranwal S., et al, Role of active efflux in association with target gene mutations in fluoroquinolone resistance in clinical isolates of Vibrio cholerae. Antimicrob Agents Chemother, 2002. 46(8): p. 2676-8. PMID: 12121955
11. Kumar P., et al, Haitian variant ctxB producing Vibrio cholerae O1 with reduced susceptibility to ciprofloxacin is persistent in Yavatmal, Maharashtra, India, after causing a cholera outbreak. Clin Microbiol Infect, 2014. 20(5): p. O292-3. doi: 10.1111/1469-0691.12393 PMID: 24102849
12. Islam M.S., et al, Susceptibility to fluoroquinolones of Vibrio cholerae O1 isolated from diarrheal patients in Zimbabwe. JAMA, 2009. 302(21): p. 2321-2. doi: 10.1001/jama.2009.1750 PMID: 19952318
13. Khan W.A., et al, Comparative trial of five antimicrobial compounds in the treatment of cholera in adults. Trans RSoc Trop Med Hyg, 1995. 89(1): p. 103-6. PMID: 7747291
14. Khan W.A., et al, Randomised controlled comparison of single-dose ciprofloxacin and doxycycline for cholera caused by Vibrio cholerae 01 or 0139 [see comments]. Lancet, 1996. 348(9023): p. 296-300. PMID: 8709688
15. Salam, M.A., et al, The Quest for New Drug in the Treatment of Cholera in Adults: Evaluation of Efficacy of Rifaximin in a Randomized, controlled Clinical Trial, in 40th US-Japan Cholera Meeting. 2005: Boston.
16. Calia K.E., et al., Comparison of Vibrio cholerae O139 with V. cholerae O1 classical and El Tor bio-types. Infection and immunity, 1994. 62(4): p. 1504-1506. PMID: 7510671
17. NCCLS, Approved Standards M2-A6. Performance standards for antimicrobial disk susceptibility tests. National Committee for Clinical Laboratory Standards. Vol. 6th ed. NCCLS. 1997, Wayne, PA: National Centre for Clinical Laboratory Standards.
18. CLSI, Approved document M100-S24. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Fourth Informational Supplement. 2014.
19. Hakanen A., et al, Detection of decreased fluoroquinolone susceptibility in Salmonellas and validation of nalidixic acid screening test. J Clin Microbiol, 1999. 37(11): p. 3572-7. PMID: 10523554
20. Launay O., et al, Typhoid fever due to a Salmonella typhi strain of reduced susceptibility to fluoroquinolones. Clin Microbiol Infect, 1997. 3(5): p. 541-544. PMID: 11864178
21. Nguyen J.C. and Goldstein F.W., Low-level resistance to fluoroquinolones among Salmonella and Shigella. Clin Microbiol Infect, 2000. 6(4): p. 231. PMID: 11168117
22. Horiuchi S., et al, Reduced susceptibilities of Shigella sonnei strains isolated from patients with dysentery to fluoroquinolones. Antimicrob Agents Chemother, 1993. 37(11): p. 2486-9. PMID: 8285640
23. Thwaites R.T. and Frost J.A., Drug resistance in Campylobacter jejuni, Ccoli, and C lari isolated from humans in north west England and Wales, 1997. J Clin Pathol, 1999. 52(11): p. 812-4. PMID: 10690169
24. Bhattacharya M.K., et al., Outbreak of cholera caused by Vibrio cholerae 01 intermediately resistant to norfloxacin at Malda, West Bengal. J Indian Med Assoc, 2000. 98(7): p. 389-90. PMID: 11143861
25. Jesudason M.V., Balaji V., and Thomson C.J., Quinolone susceptibility of Vibrio cholerae O1 &O139 isolates from Vellore. Indian J Med Res, 2002. 116: p. 96-8. PMID: 12619447
26. Jesudason M.V. and Saaya R., Resistance of Vibrio cholerae 01 to nalidixic acid. Indian J Med Res, 1997. 105: p. 153-4. PMID: 9145595
27. Jacoby G.A., Mechanisms of resistance to quinolones. Clin Infect Dis, 2005. 41 Suppl2: p. S120-6. PMID: 15942878
28. Knapp J.S., et al, Proposed criteria for interpretation of susceptibilities of strains of Neisseria gonorrhoeae to ciprofloxacin, ofloxacin, enoxacin, lomefloxacin, and norfloxacin. Antimicrob Agents Chemother, 1995. 39(11): p. 2442-5. PMID: 8585723
29. Dutta P., et al, Ciprofloxacin susceptible Salmonella typhi with treatment failure. J Trop Pediatr, 2001. 47(4): p. 252-3. PMID: 11523770
30. Chandel D.S. and Chaudhry R., Enteric fevertreatmentfailures: aglobal concern. Emerg Infect Dis, 2001. 7(4): p. 762-3. PMID: 11585550
31. Kadhiravan T., et al., Clinical outcomes in typhoid fever: adverse impact of infection with nalidixic acid-resistant Salmonella typhi. BMC Infect Dis, 2005. 5(1): p. 37.
32. Wain J., et al, Quinolone-resistant Salmonella typhi in Viet Nam: molecular basis of resistance and clinical response to treatment. Clin Infect Dis, 1997. 25(6): p. 1404-10. PMID: 9431387
33. Crump J.A., et al, Reevaluating fluoroquinolone breakpoints for Salmonella enterica serotype Typhi and for non-Typhisalmonellae. Clin Infect Dis, 2003. 37(1): p. 75-81. PMID: 12830411
34. Huang D.B. and DuPont H.L., Rifaximin a novel antimicrobial for enteric infections. Journal of Infection, 2005. 50(2): p. 97-106. PMID: 15667909
35. Ng L.K., et al, Can Etest be used to determine Vibrio cholerae susceptibility to erythromycin? Antimicrob Agents Chemother, 2003. 47(4): p. 1479-80. PMID: 12654699
36. NCCLS, Performance Standards for Antimicrobial Susceptibility Testing: Twelfth Informational Supplement. NCCLS document M100-S12, 2002.
37. Wells, J.G., Manual for the Laboratory Identification and Antimicrobial Susceptibility Testing of Bacterial Pathogens of Public Health Importance in the Developing World, in Haemophilus influenzae, Neisseria meningitides, Streptococcus pneumoniae, Neiseseria gonorrhoeae, Salmonella serotype Typhi, Shigella, and Vibrio cholerae, M.J. Perilla, et al., editors. 2003, Switzerland: Geneva.
38. Emergence of a unique, multi-drug resistant strain of Vibrio cholerae O1 in Bangladesh. http://www.icddrb.org/pub/publication.jsp?classificationID=56&pubID=6298 (accessed August 20, 2005). Health and Science Bulletin (English) Vol. 3 No. 2 Jun 2005, 2005. 3(2): p. 1-20.